Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a publicly traded biomedical company focused on developing and commercializing medical devices targeting cardiovascular and other chronic conditions. The company entered public markets through a SPAC merger that closed in 2023 and currently trades on Nasdaq. On June 16, 2026, Orchestra BioMed filed a DEFA14A — additional definitive proxy materials — with the SEC in connection with an active shareholder solicitation process. Orchestra BioMed operates in the medical devices and life sciences sector, with its lead program centered on the BackBeat cardiac neuromodulation system for hypertension management. For full proxy history, SPAC lineage, and real-time filing alerts on OBIO, create a free account at SpacDesk.